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Paternally-inherited loss-of-function mutations in makorin ring finger protein 3 gene
(MKRN3) underlie central precocious puberty. To investigate the puberty-related
mechanism(s) of MKRN3 in humans, we generated two distinct bi-allelic MKRN3
knock-out human pluripotent stem cell lines, Del 1 and Del 2, and differentiated them
intoGNRH1-expressing neurons. Both Del 1 and Del 2 clones could be differentiated into
neuronal progenitors and GNRH1-expressing neurons, however, the relative expression
of GNRH1 did not differ from wild type cells (P = NS). Subsequently, we investigated
stable and dynamic protein-protein interaction (PPI) partners of MKRN3 by stably
expressing it in HEK cells followed by mass spectrometry analyses. We found 81
high-confidence novel protein interaction partners, which are implicated in cellular
processes such as insulin signaling, RNA metabolism and cell-cell adhesion. Of the
identified interactors, 20 have been previously implicated in puberty timing. In conclusion,
our stem cell model for generation of GNRH1-expressing neurons did not offer
mechanistic insight for the role of MKRN3 in puberty initiation. The PPI data, however,
indicate that MKRN3 may regulate puberty by interacting with other puberty-related
proteins. Further studies are required to elucidate the possible mechanisms and
outcomes of these interactions.
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INTRODUCTION
The onset of puberty is dependent on the reactivation of hypothalamic GnRH secretion, which
leads to increased gonadotropin and sex steroid secretion, secondary sex characteristics and the
attainment of adult height and fertility (1, 2). In patients with central precocious puberty (CPP),
puberty starts before the age of 8 years in girls (Tanner breast stage 2) and 9 years in boys (Tanner
genital stage G2) (1, 3, 4). Premature central activation of GnRH secretion may be pathological due
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to intracranial lesions, or idiopathic when no underlying cause
can be identified (4). In girls, the annual incidence of CPP varied
from 15 to 29 per 1,00,000 (5), and the overall risk and incidence
is higher in girls than in boys (2, 3, 6).
The genetic etiology of idiopathic CPP is not completely
understood, but the clinically most relevant gene underlying
CPP is makorin ring finger protein 3 gene (MKRN3) (7–11).
MKRN3 is a single-exon, maternally imprinted gene, which
is expressed only from the paternal allele (12). Consequently,
only paternally-inherited loss-of-function mutations in MKRN3
cause CPP (7, 11). MKRN3 belongs to the makorin family of
ubiquitin ligases together with MKRN1 and MKRN2. MKRN3
is a close relative of MKRN1, being an intronless retrocopy of
the latter (12, 13). Similar to other makorin family members,
MKRN3 too consists of three zinc finger domains (C3H), one
zinc RING finger domain (C3HC4) and one MKRN3-specific
Cys-His domain (CH) and is expressed ubiquitously in human
fetal and adult tissues (13, 14). Based on its structure, MKRN3
is predicted to function as a putative E3-ubiquitin ligase and it
potentially affects gene expression, targeted protein degradation
and protein function modulation via its E3 ligase activity (12–
15). Interestingly,MKRN3 is expressed in the mouse and human
hypothalamus (7, 8), but the mechanistic processes by which
a paternally inherited loss-of-function MKRN3 mutation causes
CPP are currently unclear.
Human pluripotent stem cells (hPSCs) have the indefinite
capability of self-renewal and they can be differentiated into
specialized cell types (16). To this end, we have recently described
a protocol for the differentiation of GNRH1-expressing neurons
from hPSCs (17), which offers a possibility to investigate the
role of genetic factors in the regulation of GNRH1 in humans.
Clustered Regularly Inter Spaced Palindromic Repeats (CRISPR)
and CRISPR-associated protein 9 (CRISPR/Cas9) has become
a prevailing technology in the area of gene editing (18). In
brief, the CRISPR/Cas9 approach comprises of a short guide
RNA (crRNA) fused to bacterial-specific trans-activating crRNA
called tracrRNAwhich processes the crRNA, the fusion of crRNA
and tracrRNA forms tracr:cr RNA complex which directs the
Cas9 enzyme to a specific locus on DNA, generating double
strand breaks (18). These double strand breaks are naturally
repaired by an error-prone non-homologous end joining in the
absence of a donor template (19). We utilized this technique to
generate bi-allelic MKRN3 deletions in hPSCs and differentiated
the knock-out (KO) cell lines into GNRH1-expressing neurons
by employing our recently described protocol comprising dual
SMAD inhibition, FGF8 treatment and Notch inhibition (17).
Most cellular proteins do not function in isolation, but
perform their biological functions by interacting with each other
(20). Protein-protein interactions (PPIs) form a network that
operates in a coordinative manner to bring up physiological
Abbreviations: CPP, central precocious puberty; MKRN3, makorin ring finger
protein 3; hPSCs, human pluripotent stem cells; WT, wild type; KO, knock-
out; CRISPR, clustered regularly interspaced palindromic repeats; Cas9, CRISPR
associated protein 9; bps, base pairs; gRNA, guide RNA DNA template; GFP,
green fluorescent protein; PPI, protein-protein interaction; HCI, high-confident
interactions; CHH, congenital hypogonadotropic hypogonadism.
activities within a living cell (21). Mass spectrometry (MS)
has evolved into an efficient technique in analyzing and
characterizing PPIs (20, 22). To further investigate the putative
mechanisms by which MKRN3 may affect the timing of puberty,
we investigated MKRN3 PPI partners in HEK cells by employing
our recently described MS-based approach, which allows the
detection of stable and transient interaction partners for the
protein of interest (20). This cell line was selected as a model,
since HEK cells share certain characteristics of neurons (23), are
widely available to researchers, and are frequently employed in
biomedical research.
MATERIALS AND METHODS
Human Pluripotent Stem Cells
Human pluripotent stem cell line H9 [46, XX, (Wicell)] was
used in this study (24). hPSCs were maintained on Matrigel R©
(BD Biosciences) coated dishes with StemPro (Thermo Fisher
Scientific) or Essential 8 medium (Thermo Fisher Scientific).
During maintenance, the cells were split with 0.5mM EDTA
(Thermo Fisher Scientific, MA) and plated in 1:3–1:8 ratios.
Medium was changed daily and before the differentiation, cells
were plated on Geltrex-coated dishes (Thermo Fisher Scientific)
and grown until >90% confluency.
Guide RNA Design and Production
CRISPR guides were designed using https://benchling.com/ to
target the only exon of MKRN3. Based on their off-target and
specificity scores, two pairs of the best possible guides were
selected. Guide RNA DNA templates (gRNAs) were prepared by
PCR (gRNA-PCR) amplification based on a method previously
published (25). In brief, gRNA templates having 19 bp overhangs
on 5′ and 3′ ends were fused to U6 promoter and terminator
sequences (tracr) using PCR mentioned above with Phusion
polymerase (Thermo Fisher Scientific). Further information on
the gRNA-PCR is given in the Supplementary Material. All the
CRISPR related oligos and guide sequences have been listed in
Supplementary Table 1.
Generating CRISPR/Cas9 Based MKRN3
KO Cell Lines
For generating MKRN3 KO in hPSCs, two gRNAs targeting
different locations of MKRN3 and a plasmid encoding wild
type (WT) Streptococcus pyogenes Cas9 (SpCas9, referred as
Cas9 hereafter), Green fluorescent protein (GFP) and puromycin
resistance gene were electroporated to two million H9 cells with
the Neon transfection system according to the manufacturer’s
instructions (Thermo Fisher Scientific). A total of 4 µg plasmid
DNA and 250 ng of each gRNA was used per electroporation,
and the electroporated cells were plated on Matrigel R©-coated
dishes and supplemented with 10µM ROCK inhibitor (Y-
27632 2HCl, Selleckchem) to enhance survival of hPSCs by
inhibiting dissociation-induced apoptosis (26). Culture medium
was changed every 24 h, with transient selection of surviving
clones using 0.12µg/ml puromycin (Sigma-Aldrich) starting
after 48 or 72 h.
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Colony-Picking or Fluorescence Activated
Cell Sorting (FACS)
After 48 h of puromycin selection, emerging colonies were either
manually picked or single cell sorted using a flow sorter (Sony
Biotechnology Inc.). Manual picking of the colonies was carried
out using a 10 µl pipette and Stereozoom R©S4E light microscope
(Leica microsystems). The individual colonies were identified
under microscope and manually detached. Colonies were plated
in a single well of a Matrigel R© coated 96-well tissue culture plate
(Sarstedt) containing E8 cell culture medium, supplemented with
10µM ROCK inhibitor.
For cell sorting, Sony SH800 flow sorter was used to sort
GFP positive (indicating successful entry of Cas9 plasmid) single
cells, which were then plated on each well of the 96 well-plates
containing E8 cell culture medium supplemented with 10µM
ROCK inhibitor. During both manual picking and cell sorting,
medium was refreshed every 48 h (without ROCK inhibitor and
puromycin) and the colonies were grown until they reached
70–80% confluency.
PCR-Based Screening of All the Surviving
Clones
Genomic DNA (gDNA) from all the surviving colonies
originating from single colonies or cells, were isolated using
Direct cell PCR lysis buffer (Viagen Biotech) supplemented
with 20µg/ml of Proteinase K (Thermo Fisher Technologies).
The gDNA served as a template to identify cell lines with bi-
allelic or mono-allelic deletion using a specific primer pair-
based PCR screening with AmpliTaq gold DNA polymerase
(Thermo Fisher Scientific). Conditions for screening PCR’s are
provided in Supplementary Material, primers used are listed in
Supplementary Table 2.
Targeted Sequencing of MKRN3 KO Cell
Lines
gDNA from WT and the MKRN3 KO cell lines were PCR
amplified with primers 200 bps upstream and downstream of
MKRN3 and the product was purified using A’SAP PCR clean up
kit (Arcticzymes) according to the manufacturer’s instructions.
The purified PCR products were subjected to Next generation
sequencing using Nextera DNA library preparation kit (Illumina
Technologies) performed at the Institute for Molecular Medicine
Finland (FIMM, Helsinki). The targeted sequencing data was
analyzed with the Integrative Genomics Viewer (IGV) tool from
Broad institute (27). The primers used for targeted sequencing of
MKRN3 are listed in Supplementary Table 2.
Differentiation of hPSCs to
GNRH1-Expressing Neurons
At >90% confluency, both WT and MKRN3 KO hPSCs were
differentiated into GNRH1-expressing neurons as described
in Lund et al. (17). Briefly, the cells were treated with
2µM Dorsomorphin (Selleckchem) and 10µM SB431542
(Sigma-Aldrich) for 10 days to produce neuro-ectoderm,
a further 10 days with 100 ng/ml FGF8 (Peprotech), and
differentiation into post-mitotic neurons was stimulated by
Notch inhibition using 20µM DAPT (Sigma-Aldrich). The
successful differentiation into GNRH1-expressing neurons was
confirmed by morphological analysis, antibody staining to
identify GnRH expressing cells and qPCR.
RNA Isolation and Reverse Transcription
RNA extraction (Nucleospin RNA, Machery-Nagel) and
cDNA synthesis by reverse transcription (iScript
TM
cDNA kit,
BIO-RAD) were performed according to the manufacturer’s
instructions except that DNase treatment during RNA extraction
was performed separately with RQ1 DNase (Promega), 1U/µg
RNA, in presence of RNase inhibitor (Promega). The reverse
transcription was performed in a regular thermal cycler with 1
µg of total RNA using iScript
TM
mix containing a blend of oligo
(dT) and random hexamer primers. Conditions for RT PCR are
provided in the Supplementary Material.
Analysis of GNRH1 Expression
The expression levels of GNRH1 gene were measured by qPCR,
normalized to Cyclophilin G (PPIG) and compared to expression
in undifferentiated PSCs, as previously described (17). The
normal range for GNRH1 mRNA expression in WT cells was
determined based on nine differentiation experiments (n = 9).
Day 25, was used to characterize GNRH1 expression in our
protocol (17), and the same day was selected here for comparison
of WT (n = 9) and MKRN3 KO cell lines (n = 6) in all
the experiments. Conditions for qPCR are provided in the
Supplementary Material, the primers used in qPCR are listed in
Supplementary Table 2.
Immunocytochemistry
The cells were fixed using 4% paraformaldehyde for 15min
at room temperature (RT) and permeabilized for 7min in
0.5% Triton X-100 (Sigma-Aldrich) diluted in PBS. Unspecific
binding was blocked with UltraVision Protein Block (Thermo
Fisher Scientific) for 10min. Primary antibody incubation
was performed overnight at 4◦C and secondary antibody
for 1 h at RT. Antibodies were diluted in PBS containing
0.1% Tween 20 (Sigma-Aldrich). Slides were mounted using
VECTASHIELD R© Mounting Medium with DAPI (Vector
laboratories) for counterstaining the nuclei and microscopic
images were obtained using ZEISS Axio Imager.Z2 upright
epifluorescent microscope (Zeiss) using 10x/NA 0.3 and 20x/NA
0.8 EC PL APO CS2 objectives (Biomedicum Imaging Unit) and
analyzed with ImageJ (NIH). All the antibodies and dilutions are
listed in Supplementary Table 3.
Generation of Stable Expression Cell Line
and Cell Culture for Protein-Protein
Interaction Studies in HEKs
For the generation of stable and inducible cell lines, gateway
cloning (28) was employed to create MKRN3 expression vector.
MKRN3 PCR-product with flanking site specific attachment sites
(attB) and donor vector with site specific attachment sites (attP)
were recombined by BP reaction to get the gateway compatible
entry clone. Recombination between attB and attP sites results
in attL and attR sites which are recombined by LR reaction
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between the entry clones and the MAC-C destination vector
(20) to generate the MAC-tagged MKRN3 expression vector.
Flp-In
TM
293 T-REx cell lines (Invitrogen, Life Technologies,
R78007) were co-transfected with the expression vector and the
pOG44 vector (Invitrogen) using the DreamFect
TM
reagent (Oz
Biosciences). Two days after transfection, culture medium was
changed toDMEM/F12 (Thermo Fisher Scientific) supplemented
with 10% FBS, 50 mg/mL penicillin, 50 mg/mL streptomycin
(Sigma-Aldrich) and hygromycin B (Thermo Fisher Scientific)
(100µg/mL). The hygromycin B selection for isogenic clones was
performed for 2 weeks.
The stable cell line was expanded to 30 × 150mm plates.
When cells reached 80% confluency, 1µg/ml tetracycline (Sigma-
Aldrich) was added for 24 h to express MAC-tagged MKRN3.
For biotinylation labeling (BioID), 50µM additional biotin
(Thermo Fisher Scientific) was added at the same time with
tetracycline. Cells deriving from 5 × 150mm fully confluent
dishes (approximately 5 × 107 cells) were pelleted as one
biological replicate. Three biological replicates for each condition
and in total six biological replicates for two different conditions
(with and without biotin) were collected. Samples were snap
frozen at−80◦C until further use.
Affinity Purification of Protein Complexes
and Mass Spectrometry (MS)
The cells with only tetracycline induction were used for affinity
purification (29). The cells treated with tetracycline and biotin
were applied for BioID purification as previously described
(20). Purified protein complexes (AP-MS)/proteins (BioID) were
processed and digested to peptides for MS analysis. The analysis
was performed on Qrbitrap Elite hybrid mass spectrometer using
Xcalibur version 2.0.7 SP1 (Thermo Scientific) coupled with an
EASY nLC 1000-reverse phase HPLC system via an electrospray
ionization sprayer (Thermo Fisher Scientific). MS was performed
in data-dependent acquisition mode using Fourier transform
mass spectrometry full scan (300–1,700 m/z) resolution of
60,000 and collision-induced dissociation scan of top 20 most
abundant ions.
Data Processing
For protein identification, Thermo.RAW files were searched
against reviewed selected human UniProtKB/SwissProt database
(http://www.uniprot.org/, version 2017-02) with SEQUEST
search engine. The decoy database was the reverse of the target
database. All data were reported based on 95% confidence for
protein identification, as determined by the false discovery rate
(FDR) ≤5%. Contaminant Repository for Affinity Purification
(CRAPome, http://www.crapome.org/) (30) database and in-
house GFP samples database were used as controls with a cut-
off frequency of 20% (411 runs from CRAPome database and
100 runs of in house GFP control samples) for identification of
high-confidence interactions (HCIs). HCIs data were imported
into Cytoscape 3.4.0 to construct protein interaction network.
The known prey-prey interaction data were obtained from IMEx
database (http://www.imexconsortium.org/) (31). Gene ontology
classification analysis was based on DAVID bioinformatics
resource (https://david.ncifcrf.gov/) (32). We also compared the
HCI partners of MKRN3 with proteins encoded by 371 genes,
that are associated with puberty timing according to large
population based studies (33, 34). In addition, we investigated the
HCIs to proteins encoded by 37 genes implicated in congenital
hypogonadotropic hypogonadism (CHH) (35–40).
Statistics
The relative GNRH1 expression in WT H9 and MKRN3 KO
cell lines Del 1 and Del 2 was tested with unpaired t-test after
logarithmic transformation to normalize the distributions. P-
value < 0.05 was accepted to indicate statistical significance.
RESULTS
CRISPR/Cas9 Based Generation of MKRN3
KO Cell Lines in hPSCs
To investigate the impact of MKRN3 deficiency in the
differentiation of GNRH1-expressing neurons, we generated
two hPSC lines with bi-allelic deletions of MKRN3 using
CRISPR/Cas9. Bi-allelic KO cell lines were generated, as
heterozygousMKRN3mutations cause CPP only when inherited
from the father, and we could not selectively target the desired
deletion to the paternal allele. The schematic indicates the guide
targeting areas and deletions in these cell lines (Figure 1A).
In brief, two pairs of RNA guides spanning different lengths
on the only exon of MKRN3 together with Cas9 resulted in
deletions of either −174 or −901 bps. For further studies, we
chose two apparently homozygous KO lines Del 1 (small deletion,
−174 bps), and Del 2 (large deletion, −901 bp), which were
validated to carry desired deletions by PCR (Figure 1B) and
targeted sequencing Supplementary Figures 1, 2). The absence
of functional MKRN3 expression was further validated by
performing PCR with cDNAs from the WT andMKRN3 KO cell
lines as template and with primers flanking the deletion regions
(Figure 2A). The length of the transcripts produced from the KO
clones corresponded to the size of deletions seen at DNA level
(Figure 2B), consistent with the bi-allelic deletion in the coding
region ofMKRN3.
Differentiation of MKRN3 KO and WT
hPSCs to GNRH1- Expressing Neurons
We next differentiatedMKRN3 KO cell lines Del 1 and Del 2 into
GNRH1-expressing neurons, according to our recently described
protocol (Figure 3A) (17). Both cell lines could be differentiated
into neuronal progenitors and further into GNRH1-expressing
neurons (Figure 3B). At day 25 of differentiation the relative
GNRH1mRNA expression between theMKRN3KO cell lines and
WT H9 cells (Figure 3C), did not differ (P = NS). The mRNA
expression levels of OTX2, a transcriptional regulator of GNRH1
(41), together with OTX1, both of which are enriched in GnRH-
neurons of mice (42) were not significantly different betweenWT
and Del 2 (n =3) cells at day 25 of the differentiation protocol
(Supplementary Figure 3).
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FIGURE 1 | CRISPR/Cas9-based generation of two bi-allelic MKRN3 KO cell lines (Del 1 and Del 2) in human pluripotent stem cell line H9 and verification of
CRISPR/Cas9 induced deletions at genomic DNA level. (A) Left panel, Del 1 has a deletion of 174 bps, translating to a deletion of 51 amino acids (11% of protein)
including the translation start site. Right panel, Del 2 has a deletion of 901 bps, translating to 300 amino acid deletion (60% of protein). (B) The presence or absence
of CRISPR/Cas9-induced deletions in MKRN3 was verified by PCR amplification of the region of interest from genomic DNA of WT human pluripotent H9 cells, and in
CRISPR/Cas9 edited cells. Four examples of edited cell lines are shown (Del 1–Del 4). The same pair of guide RNAs, designed to delete ∼900 bps, was used for
editing Del 2 and Del 3 cell lines, whereas two different gRNA pairs were used to edit Del 1 and Del 4 cell lines. The PCR products were visualized on a 1.5% agarose
gel.
FIGURE 2 | (A) Schematic of MKRN3 cDNA and the two pairs of primers (green and blue arrows) employed in detection of WT, Del 1, (left panel) and Del 2, (right
panel). cell lines. In WT cells, the expected product sizes are 305 and 1,235 bp, in Del 1 cells 131 bp and in Del 2 cells 334 bp. (B) MKRN3 amplification from the
cDNA of the two bi-allelic MKRN3 deletion cell lines Del 1, (left panel) and Del 2, (right panel). White arrow indicates the expected wild type (WT) product sizes (305
and 1,235 bp, respectively) and the red arrows indicate the expected sizes (131 and 334 bp, respectively) for the PCR products from Del 1 and Del 2 cell lines. The
cDNA used is from day 25 of the protocol generating GNRH1-expressing neurons. The PCR products were visualized on a 1.5% agarose gel.
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FIGURE 3 | (A) Schematic for the generation of GNRH1-expressing neurons from hPSCs (17). In brief, dual SMAD inhibition by Dorsomorphin and SB431542 was
applied for the first 10 days, followed by 10 days of FGF8 treatment and final stage of neuronal maturation for 5–7 days by combining FGF8 with Notch inhibition by
DAPT. This differentiation methodology has been adapted from a previously published protocol and the figure has been modified from the original publication by Lund
et al. (17). (B) Immunocytochemistry in WT and Del 2 derived day 25 GnRH-positive neurons (green) nuclear stained with DAPI (blue), scale bars represent 100µM.
(C) The relative expression of GNRH1 in WT H9 cells (n = 9) and in two bi-allelic MKRN3 KO cell lines (Del 1 and Del 2) following three independent repeats (n = 6) of
differentiation into GNRH1-expressing neurons (17). Expression levels are relative to day 0 hPSCs.
MKRN3 and Its Protein Interaction Partners
Using MS analysis, we identified 104 HCIs including
both transient and stable interactions for MKRN3
(Supplementary Table 4). These 104 HCIs total for 81 unique
HCIs (Figure 4), were classified into functional groups according
to their annotation categories involved in various pathways
regulating cellular processes, mainly the regulation of insulin
secretion, cell-cell adhesion, TP53-regulated cell metabolism,
transcriptional repression and RNA activity related interactors
(32). Importantly, our MS data revealed that MKRN3 physically
interacts with as many as 19 proteins (including LIN28B)
encoded by genes, which have been previously associated with the
age at menarche (33, 34). In addition,MS data identified OTUD4,
a protein implicated in CHH (43), as HCI partner for MKRN3.
DISCUSSION
In mice, expression of Mkrn3 decreases during postnatal
development, and in humans, circulatingMKRN3 levels decrease
toward the onset of puberty in both sexes (44, 45). However,
investigation of peripheral MKRN3 levels does not allow for
mechanistic explanation of the role of MKRN3 in regulation
of puberty in humans. Therefore, we employed our recently
described differentiation protocol generating GNRH1-expressing
neurons (17) and genetically engineered hPSCs to investigate
if MKRN3 is required for GnRH neuron differentiation in this
model. In addition, we investigated PPI partners of MKRN3
in HEK cells and paid special attention to possible interactors
encoded by puberty-related genes.
Although several studies have reported that paternally
inherited mutations in MKRN3 cause CPP (46), the underlying
mechanisms still remain to be explained (1, 2). In our study,
we first examined the role of MKRN3 on GNRH1 expression
by using two bi-allelic MKRN3 KO clonal cell lines (Del 1
and Del 2), generated with CRISPR/Cas9 technology. These cell
lines were subsequently differentiated into GNRH1-expressing
neurons through our recently described differentiation protocol,
which is based on dual SMAD inhibition, FGF8 treatment and
Notch inhibition (17). Our results show that both the Del 1 and
Del 2 cell lines could be successfully differentiated into GNRH1-
expressing neurons, suggesting that MKRN3 is dispensable for
the differentiation. Intriguingly, GNRH1 expression of Del 1
and Del 2 cell lines did not differ from the controls, which
suggests that MKRN3 does not directly alter GNRH1 expression.
However, there are many environmental and metabolic signals
postnatally, that may regulate further maturation and function
of GnRH neurons (47, 48). While MKRN3 does not affect the
GnRH neuron differentiation or their ability to express GNRH1
in our model, there are other potential mechanisms by which
MKRN3 may regulate GnRH neuron function. For example,
major regulation of GnRH neuron activity is carried out by
Kisspeptin and KNDy neurons in the hypothalamus, and putative
role of MKRN3 on these neurons is not known. The possibility of
other MKRNs compensating for the loss of MKRN3 in Del 1 and
Del 2 cell lines cannot be ruled out. On the other hand, hPSC-
based disease modeling is the closest available approach to model
human neuronal disorders (49), and with regard to MKRN3,
murine models have not yet been reported. What is known so far,
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FIGURE 4 | Protein-protein interaction map of MKRN3. The network represents PPIs of MKRN3 detected by different purification methods. Blue edges represent
experimentally validated interaction by AP-MS; Red lines represent interactions detected by BioID purification; Overlap of two purification methods is shown with gray
color, while a dashed line describes prey-prey interactions. The colored nodes represent the different clusters of prey proteins.
however, is thatMKRN3 is not significantly enriched or depleted
in mouse GnRH neurons (42).
Given that we could not find a mechanistic cue for the
role of MKRN3 in GNRH1 expression in our stem cell model,
we considered alternative approaches to gain insight on how
this putative E3-ligase might affect puberty timing. In brief
the method investigating PPIs employs a MAC-tag system that
contains affinity tags for affinity purification-mass spectrometry
(AP-MS) as well as the biotin ligase BirA∗ for BioID. Therefore, a
single construct is sufficient to identify both stable and transient
interactions (20). We did not carry out PPI studies in our stem
cell model, since the efficient cloning of all different tagged
MKRN3 constructs to hPSCs was beyond the scope of this work.
While this is a potential caveat, it is important to note that
HEK cells, one of the most widely employed human cell lines
in biomedical research (50), are not unsuitable for our purpose
since they exhibit some neuronal properties (23). In addition,
our laboratory is extremely experienced in using HEK cell line-
based platform, which allows rapid and efficient generation of
expression constructs and subsequent data analysis. Based on
the list of HCI proteins for MKRN3, we found that MKRN3
might be involved in cell-cell adhesion, RNA metabolism and
insulin secretion. Insulin has been suggested to modify GnRH
neuron function in humans, and insulin sensitivity is thought
to be an important factor in the initiation of puberty (1, 51, 52).
MKRN3 interacts with a group of proteins encoded by metabolic
genes, which in turn, are regulated by TP53, a tumor suppressor
gene involved in several cancers and implicated in puberty (53).
Other PPI partners of MKRN3 are involved in RNA transport
and metabolism, which remains less explored areas in terms
of puberty.
In addition, we found that MKRN3 interacts with 20 proteins
encoded by puberty timing-associated genes of which LIN28B
is one of the most established puberty-related genes in genetic
studies (54, 55) and OTUD4 represents the only puberty-related
disease gene (43). Although LIN28B has been associated with
the age at menarche, adult height and childhood growth (56–
60), and is known to be a negative regulator of let-7 class of
microRNAs (61), the mechanism by which it regulates puberty
timing is unknown (1, 62, 63). In rats and non-human primates
Lin28b expression declines in the hypothalamus at puberty (64),
and in mice, expression of both Lin28b and Mkrn3 is reduced
prior to puberty (7, 65). Our findings provide evidence of
physical interaction between human LIN28B and MKRN3 and
it is tempting to speculate that they may act in concert to regulate
the timing of puberty. We also examined MKRN3 interactions
among 37 genes implicated in CHH (35–40), and found that
MKRN3 interacts with OTUD4. OTUD4 is a deubiquitinase
coding gene (43), and it is intriguing to hypothesize that it may
regulate the timing of puberty by counteracting the effects of
MKRN3. Further studies are required to confirm this hypothesis.
Finally, MKRN3 interacts with other zinc finger genes (ZNFs)
which are transcriptional repressors and have an important role
during puberty (66), however, we could not observe MKRN3’s
interaction with ZNFs critical for puberty onset, such as ZNF573
and GATAD1 (66). Even so, the interactions observed invite
the possibility of MKRN3 being an epigenetic transcriptional
repressor involved in puberty timing.
Frontiers in Endocrinology | www.frontiersin.org 7 February 2019 | Volume 10 | Article 48
Yellapragada et al. MKRN3-Interacting Proteins
In conclusion, our results suggest that MKRN3 is dispensable
for the GnRH neuron differentiation process and GNRH1
expression during differentiation from human pluripotent stem
cells. Although the mechanism by which MKRN3 regulates
humans sexual maturation remains unclear, our results suggest
that MKRN3 may act in concert with previously identified
puberty-related proteins, and it is enticing to hypothesize
that this interaction is translated to functional cooperation in
terms of puberty timing. Further studies are required before we
understand how and why the HPG axis activates prematurely in
children with a paternally inherited loss-of-function mutations
inMKRN3.
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